Benoit Detry

Benoit Detry

Auto-generated profile, based on publicly available information

Benoit Detry

STAR Medical SA, Avenue Sabin 6, 1300, Wavre, Belgium

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 October 2020 in BMC Biomedical Engineering
Verified
Journal Article
Open access
PDF file
IGIan Grierson
Ian Grierson
DMDon Minckler
Don Minckler
MRMarian K. Rippy
Marian K. Rippy
AMAndrew J. Marshall
Andrew J. Marshall
NCNathalie Collignon
Nathalie Collignon
Murray JohnstoneMurray Johnstone
Murray Johnstone
Background: A major challenge for any glaucoma implant is their ability to provide long-term intraocular pressure lowering efficacy. The formation of a low-permeability fibrous capsule around the device often leads to obstructed drainage channels, which may impair the drainage function of devices. These foreign body-related limitations point to the need to develop biologically inert biomaterials to improve performance in reaching long-term intraocular pressure reduction. The aim of this study was to evaluate in vivo (in rabbits) the ocular biocompatibility and tissue integration of a novel suprachoroidal microinvasive glaucoma implant, MINIject™ (iSTAR Medical, Wavre, Belgium). Results: In two rabbit studies, no biocompatibility issue was induced by the suprachoroidal, ab-externo implantation of the MINIject™ device. Clinical evaluation throughout the 6 post-operative months between the sham and test groups were similar, suggesting most reactions were related to the ab-externo surgical technique used for rabbits, rather than the implant material itself. Histological analysis of ocular tissues at post-operative months 1, 3 and 6 revealed that the implant was well-tolerated and induced only minimal fibroplasia and thus minimal encapsulation around the implant. The microporous structure of the device became rapidly colonized by cells, mostly by macrophages through cell migration, which do not, by their nature, impede the flow of aqueous humor through the device. Time-course analysis showed that once established, pore colonization was stable over time. No fibrosis nor dense connective tissue development were observed within any implant at any time point. The presence of pore colonization may be the process by which encapsulation around the implant is minimized, thus preserving the permeability of the surrounding tissues. No degradation nor structural changes of the implant occurred during the course of both studies. Conclusions: The novel MINIject™ microinvasive glaucoma implant was well-tolerated in ocular tissues of rabbits, with observance of biointegration, and no biocompatibility issues. Minimal fibrous encapsulation and stable cellular pore colonization provided evidence of preserved drainage properties over time, suggesting that the implant may produce a long-term ability to enhance aqueous outflow.

19 January 2012 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
LHLorin Host
Lorin Host
APAlexandra Paye
Alexandra Paye
BDBenoit Detry
Benoit Detry
SBSilvia Blacher
Silvia Blacher
CMCarine Munaut
Carine Munaut
ANAgnes Noel
Agnes Noel
Membrane‐type 4 matrix metalloprotease (MT4‐MMP) expression in breast adenocarcinoma stimulates tumor growth and metastatic spreading to the lung. However, whether these pro‐tumorigenic and pro‐metastatic effects of MT4‐MMP are related to a proteolytic action is not yet known. Through site directed mutagenesis MT4‐MMP has been inactivated in cancer cells through Glutamic acid 249 substitution by Alanine in the active site. Active MT4‐MMP triggered an angiogenic switch at day 7 after tumor implantation and drastically accelerated subcutaneous tumor growth as well as lung colonization in recombination activating gene‐1‐deficient mice. All these effects were abrogated upon MT4‐MMP inactivation. In sharp contrast to most MMPs being primarily of stromal origin, we provide evidence that tumor‐derived MT4‐MMP, but not host‐derived MT4‐MMP contributes to angiogenesis. A genetic approach using MT4‐MMP‐deficient mice revealed that the status of MT4‐MMP produced by host cells did not affect the angiogenic response. Despite of this tumor intrinsic feature, to exert its tumor promoting effect, MT4‐MMP requires a permissive microenvironment. Indeed, tumor‐derived MT4‐MMP failed to circumvent the lack of an host angio‐promoting factor such as plasminogen activator inhibitor‐1. Overall, our study demonstrates the key contribution of MT4‐MMP catalytic activity in the tumor compartment, at the interface with host cells. It identifies MT4‐MMP as a key intrinsic tumor cell determinant that contributes to the elaboration of a permissive microenvironment for metastatic dissemination.

1 March 2005 in The Veterinary Journal
Verified
Journal Article
Closed access
CCC. Cambier
C. Cambier
NPN. Di Passio
N. Di Passio
TCT. Clerbaux
T. Clerbaux
HAH. Amory
H. Amory
VMV. Marville
V. Marville
PGP. Gustin
P. Gustin

11 March 2010 in PLOS ONE
Verified
Journal Article
Open access
PDF file
FBFrançoise Bruyère
Françoise Bruyère
LMLaurence Melen-Lamalle
Laurence Melen-Lamalle
SBSilvia Blacher
Silvia Blacher
BDBenoît Detry
Benoît Detry
AMAnne Masset
Anne Masset
ANAgnes Noel
Agnes Noel
The purpose of this study is to explore the function of plasminogen activator inhibitor-1 (PAI-1) during pathological lymphangiogenesis. PAI-1, the main physiological inhibitor of plasminogen activators is involved in pathological angiogenesis at least by controlling extracellular proteolysis and by regulating endothelial cell survival and migration. Protease system's role in lymphangiogenesis is unknown yet. Thus, based on its important pro-angiogenic effect, we hypothesized that PAI-1 may regulate lymphangiogenesis associated at least with metastatic dissemination of cancer cells. To address this issue, we studied the impact of PAI-1 deficiency in various murine models of tumoral lymphangiogenesis. Wild-type PAI-1 proficient mice were used as controls. We provide for the first time evidence that PAI-1 is dispensable for tumoral lymphangiogenesis associated with breast cancers either induced by mammary carcinoma cell injection or spontaneously appearing in transgenic mice expressing the polyomavirus middle T antigen (PymT) under the control of a mouse mammary tumor virus long-terminal repeat promoter (MMTV-LTR). We also investigated inflammation-related lymphatic vessel recruitment by using two inflammatory models. PAI-1 deficiency did neither affect the development of lymphangioma nor burn-induced corneal lymphangiogenesis. These novel data suggest that vascular remodelling associated with lymphangiogenesis and angiogenesis involve different molecular determinants. PAI-1 does not appear as a potential therapeutic target to counteract pathological lymphangiogenesis.

1 October 2002 in The Veterinary Journal
Verified
Journal Article
Closed access
BDB. Detry
B. Detry
CCC. Cambier
C. Cambier
AFA. Frans
A. Frans
PGP. Gustin
P. Gustin
TCT. Clerbaux
T. Clerbaux